Apellis Pharmaceuticals (FRA:1JK) Accounts Payable & Accrued Expense : €117.9 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Apellis Pharmaceuticals Accounts Payable & Accrued Expense?

Apellis Pharmaceuticals's quarterly accounts payable & accrued expense increased from Sep. 2023 (€126.8 Mil) to Dec. 2023 (€151.6 Mil) but then declined from Dec. 2023 (€151.6 Mil) to Mar. 2024 (€117.9 Mil).

Apellis Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2021 (€106.3 Mil) to Dec. 2022 (€125.1 Mil) and increased from Dec. 2022 (€125.1 Mil) to Dec. 2023 (€151.6 Mil).

Apellis Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Apellis Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Accounts Payable & Accrued Expense Chart

Apellis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

56.83

98.98

106.33

125.06

151.60

Apellis Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															95.96	115.57	126.76	151.60	117.93

Apellis Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Apellis Pharmaceuticals (FRA:1JK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (FRA:1JK) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

APLS:USA

Address

100 Fifth Avenue, Waltham, MA, USA, 02451

Website

https://www.apellis.com

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

Apellis Pharmaceuticals (FRA:1JK) Headlines

No Headlines